Clearmind Medicine Inc (CMND)

Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live Webinar
Register now for free and join on June 10, 2026

Vancouver, Canada, June 05, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced it will host a live webinar titled
“Inside MEAI: Exclusive Investigator Q&A with Yale & Johns Hopkins on Wednesday, June 10, 2026, from 12:00–1:00 PM EDT (9:00–10:00 AM PDT).

Interested participants are invited to register and secure their spot in this exclusive session.

The webinar will provide an in-depth review of the latest clinical data from the Company’s ongoing FDA-approved Phase I/IIa multi-center trial evaluating CMND-100, its proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).

Featured Speakers:

Dr. Anahita Bassir Nia, MD- Assistant Professor of Psychiatry, Yale School of Medicine. Leads clinical trials on psychedelics and novel compounds for AUD, depression, and PTSD.

Dr. Jennifer Ellis, Ph.D.- Assistant Professor and licensed clinical psychologist, Johns Hopkins Medicine. Principal investigator at the Johns Hopkins trial site, focused on novel therapeutics for substance use disorders.

Dr. Adi Zuloff-Shani, Ph.D.- CEO of Clearmind Medicine, will provide a clinical development and corporate update.

Host & Moderator: The webinar will be moderated by Shannon Smadella, MBA, Co-Executive Director of World Psychedelics Day, former board member of MAPS Canada, and Special Advisor to Clearmind Medicine.

The event is open to the public and will include a live Q&A session. Registration is available via Eventbrite.

CMND..........................................p/m

cmnd............................https://stockcharts.com/sc3/ui/?s=cmnd&p=W&b=5&g=0&id=p86431144783

Tirzepatide Combination Study Expands Clearmind’s Obesity Therapy Strategy (CMND)May 18, 2026 11:17 AM
IH Market News A new preclinical research agreement positions Clearmind Medicine to evaluate whether MEAI could complement or extend the effects of blockbuster GLP-1 obesity therapies such as tirzepatide. Key Investor Takeaways The primary catalyst is Clearmind Medicine’s tirzepatide combination study involving its MEAI (CMND-100) candidate Clearmind Medicine (NASDAQ:CMND) is targeting the rapidly growing GLP-1 and obesity treatment market The study will examine whether MEAI can improve metabolic outcomes or reduce post-treatment weight regain after tirzepatide therapy Management highlighted MEAI’s prior preclinical data showing weight reduction linked to increased energy expenditure rather than appetite suppression alone The research may broaden Clearmind’s positioning beyond neuroplastogen therapeutics into obesity and metabolic health applications Why Clearmind Medicine Stock Is in Focus Clearmind Medicine announced a new research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem to conduct a 12-month preclinical study evaluating MEAI in combination with tirzepatide.The study will be led by Professor Joseph (Yossi) Tam and his team at the Obesity and Metabolism Laboratory at the Hebrew University.According to the company, the research will evaluate both concurrent use of MEAI with tirzepatide and the use of MEAI as a maintenance therapy following tirzepatide treatment in diet-induced obese mice.The company said the study aims to assess whether MEAI can help reduce post-treatment weight regain and preserve metabolic benefits after discontinuation of GLP-1 therapies.Clearmind cited previous preclinical work in which MEAI reportedly produced approximately 15% to 20% body weight reduction in obese mice through increased energy expenditure and fat utilization while preserving lean mass.“MEAI is designed to offer a differentiated mechanism that potentially complements incretin therapies,” said Dr. Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind Medicine. “While those drugs excel at reducing food intake, our previous preclinical data show MEAI significantly enhances energy expenditure. We believe that this combination and maintenance approach has potential to deliver more robust, durable, and clinically meaningful outcomes for patients.” Why This Matters for Investors The announcement may be significant because it connects Clearmind to one of the largest and fastest-growing areas in biotechnology: obesity and metabolic disease therapies.GLP-1 and dual GLP-1/GIP drugs such as tirzepatide have become major market drivers, but concerns around long-term weight maintenance and post-treatment rebound remain important industry challenges.By positioning MEAI as a potential complementary or maintenance therapy, Clearmind may be attempting to differentiate itself rather than directly compete with established GLP-1 products.The focus on energy expenditure and metabolic durability could also help shape a distinct development narrative for the company if future data supports those mechanisms.At the same time, the program remains in the preclinical stage, meaning clinical efficacy, regulatory pathways, safety outcomes, and commercialization prospects are still uncertain.The announcement also signals a strategic expansion of Clearmind’s pipeline beyond its existing focus areas tied to neuroplastogen-derived therapeutics and alcohol use disorder. What to Watch Next Investors may monitor: Initial data from the 12-month tirzepatide combination study Whether MEAI demonstrates meaningful effects on weight regain prevention Potential future clinical trial plans involving obesity or metabolic disorders Additional intellectual property filings tied to MEAI and metabolic applications Broader pipeline developments involving Clearmind’s neuroplastogen platform Clearmind Medicine stock price Original: Tirzepatide Combination Study Expands Clearmind’s Obesity Therapy Strategy (CMND)

Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications

May 16, 2026

Clearmind Medicine (Nasdaq: CMND) signed a new research agreement with Yissum to fund a 12-month preclinical study of MEAI (CMND-100) with tirzepatide in diet-induced obese mice.

The study will assess combination and maintenance use in the fast-growing $50–66B incretin therapeutics market.

Link article

$CMND 🗞️

In my opinion, the price action in the last few days is proof enough that this is a bullshit company.

$CMND hit our scanner today. #DDAmanda Chart

Similar early alerts: $WLDS $MAAS $AVEX

Lots more at: https://DDAmanda.com



Z

EXPLSIVE!🧨

CMND......................................p/m

CMND low floater with nice news this morning .. psychedelics moving nicely on the signing of Trump's Order .. similar share structure to PBM .. could get explosive

Shares Outstanding 3.85M
Public Float 1.43M — 2.02M

https://finance.yahoo.com/sectors/healthcare/articles/clearmind-medicine-announces-positive-data-113000349.html

CMND news .. Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial https://investorshub.advfn.com/stock-market/NASDAQ/clearmind-medicine-CMND/stock-news/98316921/clearmind-medicine-announced-positive-top-line-saf

Clearmind Shares Surge as CMND-100 Achieves Primary Endpoint in Clinical TrialApril 14, 2026 9:37 AM
IH Market News
Clearmind Medicine Inc. (NASDAQ:CMND) reported that its drug candidate CMND-100 successfully met the primary safety and tolerability endpoint in an FDA-approved Phase I/IIa clinical study targeting alcohol use disorder, sending the company’s shares up 40%.The Vancouver-based biotech firm said data from the trial’s third cohort demonstrated a strong safety profile for CMND-100, including at higher dose levels. The treatment was well tolerated, with no serious adverse events observed in this cohort, according to the company.CMND-100 is a proprietary, non-hallucinogenic oral therapy derived from MEAI. The ongoing Phase I/IIa study is a multinational, multicenter trial designed to assess the drug’s safety, tolerability, pharmacokinetics, and early-stage efficacy in patients with moderate to severe alcohol use disorder.The trial uses a dose-escalation approach, with the third cohort receiving the highest dosage tested so far. Clearmind said achieving the primary endpoint supports further development of CMND-100 as a potential treatment for alcohol use disorder.The company is focused on advancing what it describes as neuroplastogen-based therapies and holds an intellectual property portfolio that includes 19 patent families and 31 granted patents.Clearmind Medicine stock price

Original: Clearmind Shares Surge as CMND-100 Achieves Primary Endpoint in Clinical Trial

SciSparc’s NeuroThera Labs reports publication of international patent applicationMarch 12, 2026 11:45 AM
IH Market News
SciSparc (NASDAQ: SPRC) announced that NeuroThera Labs, a subsidiary in which it holds an approximately 75% controlling stake, has progressed its collaboration with Clearmind Medicine (NASDAQ:CMND) following the publication of an international patent application under the Patent Cooperation Treaty.The patent relates to a new combination therapy designed to target weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD).According to the companies, the patent publication outlines the potential of a treatment combining 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA). The therapy is being explored as a non-hallucinogenic neuroplastogen approach aimed at addressing two major global health conditions: obesity and MASLD.Obesity currently affects more than 890 million adults worldwide, while MASLD impacts roughly 30% of the global adult population.Based on the expected mechanism of action, the companies believe the therapy could provide a safer, more accessible and potentially lower-cost alternative to GLP-1 agonist treatments currently used for obesity and related metabolic conditions.By integrating Clearmind’s MEAI technology platform with NeuroThera’s PEA compound, the partners aim to respond to growing demand for treatments that are both effective and well tolerated in addressing obesity and liver health disorders.SciSparc stock priceClearmind Medicine stock price

Original: SciSparc’s NeuroThera Labs reports publication of international patent application

ciSparc’s NeuroThera Labs reports publication of international patent applicationMarch 12, 2026 11:45 AM
IH Market News
SciSparc (NASDAQ: SPRC) announced that NeuroThera Labs, a subsidiary in which it holds an approximately 75% controlling stake, has progressed its collaboration with Clearmind Medicine (NASDAQ:CMND) following the publication of an international patent application under the Patent Cooperation Treaty.The patent relates to a new combination therapy designed to target weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD).According to the companies, the patent publication outlines the potential of a treatment combining 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA). The therapy is being explored as a non-hallucinogenic neuroplastogen approach aimed at addressing two major global health conditions: obesity and MASLD.Obesity currently affects more than 890 million adults worldwide, while MASLD impacts roughly 30% of the global adult population.Based on the expected mechanism of action, the companies believe the therapy could provide a safer, more accessible and potentially lower-cost alternative to GLP-1 agonist treatments currently used for obesity and related metabolic conditions.By integrating Clearmind’s MEAI technology platform with NeuroThera’s PEA compound, the partners aim to respond to growing demand for treatments that are both effective and well tolerated in addressing obesity and liver health disorders.SciSparc stock priceClearmind Medicine stock price

Original: ciSparc’s NeuroThera Labs reports publication of international patent application

CMND...................................https://stockcharts.com/sc3/ui/?s=CMND&p=W&b=5&g=0&id=p86431144783

loaded 0.08

CMND.....Loaded the .1180's today.

.12 to .20 offering wall not bad 70% gain when it goes 

$CMND News!!: (Expecting a huge bounce here soon) Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
Vancouver, Canada, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced another key milestone in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD): the first participant has been enrolled and dosed with CMND-100, its proprietary MEAI-based oral drug candidate, at Hadassah-University Medical Center in Jerusalem, Israel.

Z

We are offering pursuant to this prospectus supplement and the accompanying prospectus 10,925,000 common shares, no par value, or the common shares, at an offering price of $0.20 per Common Share. Our Common Shares are currently traded on the Nasdaq Capital Market, or Nasdaq, under the symbol “CMND.” On November 18, 2025, the last reported sale price of our Common Shares on the Nasdaq was $0.216 per share. Our Common Shares also trade on the Frankfurt Stock Exchange, or FSE, under the symbol “CWY”. On November 18, 2025, the last reported sales price of our Common Shares on the FSE was EUR 0.29 (approximately $0.34) per share. 

02:20 PM EST, 11/13/2025 (MT Newswires) -- Clearmind Medicine (CMND) received final approval from Hadassah Medical Center in Jerusalem for its ongoing Phase 1/2a trial of CMND-100, an oral drug candidate based on the company's novel psychoactive compound targeting alcohol use disorder.The first cohort treatment has been successfully completed, Clearmind said Thursday in a statement.The multicenter study will evaluate the safety, tolerability, and pharmacokinetics of CMND-100, while also evaluating its potential to reduce alcohol

.24

I bought big on the dip end of last week. This thing has big potential imo

CMND......................................................p/m

$CMND: Added 50k there at $0.32

GOing nuts today............ lots of sideways action.

Gimme a nice yield babyyyyyyyyyyyyyyyyyyyyyy


GO $CMND

CMND............................................https://stockcharts.com/sc3/ui/?s=CMND&p=W&b=5&g=0&id=p86431144783

.51 +60% ....nice pump and dump get out now for me$$ advice... Preclinical studies have demonstrated MEAI’s potential to enhance mood regulation and reduce anhedonia, offering a differentiated therapeutic approach for patients who do not respond to conventional antidepressants. This patent application further reinforces Clearmind’s robust IP portfolio, which now includes protections across multiple jurisdictions for MEAI’s applications in various mental health and addiction disorders.

Pump it one more round .31

$CMND NEWS! Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment https://www.globenewswire.com/news-release/2025/11/12/3186021/0/en/Clearmind-Medicine-Announces-Notice-of-Patent-Publication-for-Depression-Treatment.html

CMND..........................https://stockcharts.com/h-sc/ui?s=CMND&p=W&b=5&g=0&id=p86431144783

I command CMND a clear Friday pump $1.12

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center
Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site.

The trial includes other first-in-class institutions, such as Yale School of Medicine’s Department of Psychiatry, Johns Hopkins University School of Medicine and Hadassah-University Medical Center in Jerusalem, Israel. The study at TASMC will be led by Dr. David Zeltser, Director of the Emergency Medicine Department and Deputy Director R&D and Innovation.

Clearmind recently announced the dosing of the first participant in the trial, marking a historic step toward developing a novel therapy for the millions affected by AUD worldwide.

IRB approval from TASMC follows Clearmind’s prior regulatory milestones, including U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application and IRB approvals from other clinical sites.

“We are pleased to receive IRB approval from Tel Aviv Sourasky Medical Center, a renowned institution, for our Phase 1/2a clinical trial,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. “This milestone brings us closer to potentially offering a transformative treatment for individuals struggling with AUD, a condition that devastates millions of lives. With TASMC’s participation, alongside leading centers like Yale and Johns Hopkins, we believe that we are well-positioned to advance our mission of developing safe, effective, and innovative psychedelic-derived therapies.”

Clearmind’s clinical trial is a critical step in addressing the global burden of AUD, which accounts for 4.7% of all deaths worldwide, according to the World Health Organization. The Company anticipates further progress in patient enrollment and data collection across its clinical sites, with the goal of delivering a breakthrough solution for those affected by AUD and their families. The Phase 1/2a clinical trial, a multinational, multi-center study, is designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also evaluating its preliminary efficacy in reducing alcohol cravings and consumption in patients with AUD.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patent

CMND...........................................................................p/m

Pump it and then short it

CMND........................................................................................p/m

Trying to get at $1.09, almost 6K shares and it doesnt bite

CMND, under$2

CMND

CMND watching this pullback close,

CMND.................https://stockcharts.com/h-sc/ui?s=CMND&p=W&b=5&g=0&id=p86431144783

Yaa gotta love the news bro!🤗

Back up 2.53 + 113% 1.86 was a dip for the flip

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD).

The trial will be led at Yale School of Medicine’s Department of Psychiatry by Dr. Anahita Bassir Nia, MD, an expert in psychiatry and addiction medicine. This milestone marks a significant step forward in Clearmind’s FDA-regulated clinical program, further expanding the multi-site trial to evaluate the safety, tolerability and efficacy of its proprietary investigational drug, CMND-100.

“Receiving the IRB approval from Yale University, takes us one step closer to commencing our innovation clinical trial with our proprietary CMND-100, for treating AUD patients,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. “Alcohol consumption is responsible for 2.6 million deaths annually worldwide, accounting for 4.7% of all global deaths, and excessive alcohol use is a leading preventable cause of death in the U.S. It remains the most commonly used substance among individuals aged 12 and older in the United States, imposing a significant economic burden with billions spent on healthcare costs. Current treatment options are limited by high costs, have low efficacy (less than 30%) and low patient compliance due to side effects1. We believe we have a unique opportunity to address this critical gap and provide an effective solution for treating this widespread condition.”

The clinical trial will assess CMND-100’s ability to reduce alcohol cravings and consumption among individuals with moderate to severe AUD. The study is designed to gather critical data supporting the advancement of CMND-100 through the clinical pipeline.

About Clearmind Medicine Inc.

Running down a little now $1.86 + 58%

Drunk high at $2.37 + 92%

CMND running

CMND running now $2.26 +
80% with 3m float

Market cap 4.4 million is insane

Big market patented product.

Thank you, Penny. I wonder if this can work.